http://www.thehugojournal.com The most accessed research articles published by The HUGO Journal 2012-03-09T00:00:00Z Fanconi Anemia (FA) is a rare disorder with incidence of 1in 350,000 births. It is characterized by progressive bone marrow failure leading to death of many patients in their childhood while development of cancer at later stages of life in some. The treatment of FA is still a medical challenge. Current treatments of FA include androgen administration, hematopoietic growth factors administration and hematopoietic stem cell transplantation (HSCT). Clinical gene therapy trials are still ongoing. The partial success of current therapies has renewed interest in the search for new treatments. Generation of patient-specific induced pluripotent stem (iPS) has shown promising results for cell and gene based therapy. Small molecule interventions have been observed to delay tumor onset in FA. Tumors deficient in FA pathway can be treated by profiling of DNA repair pathway through synthetic lethality mechanism. Targeting toll-like receptor 8 (TLR8) dependent TNFα overexpression is yet another upcoming therapeutic approach to treat FA patients. In conclusion, in the present scenario of treatments available for FA, a proper algorithm of treatment decisions must be followed for better management of FA patients and to ensure their increased survival. Innovative therapeutic approaches that can prevent both anemia and cancer should be developed for more effective treatment of FA. http://www.thehugojournal.com/content/6/1/1 Pallavi Shukla Kanjaksha Ghosh Babu Vundinti The HUGO Journal 2012, null:1 2012-03-09T00:00:00Z doi:10.1186/1877-6566-6-1 /content/figures/1877-6566-6-1-toc.gif The HUGO Journal 1877-6566 ${item.volume} 1 2012-03-09T00:00:00Z XML